Newcells Biotech Appoints Emile Shaffu as Chief Sales Officer

Newcells Biotech (“Newcells”), a leading drug discovery partner specializing in the development of in vitro models and custom analytics services to improve prediction Live human outcomes today announced the appointment of Emile Shaffu as Chief Sales Officer. With over 20 years of international sales and management experience in life sciences, his appointment is part of the company’s commercial strategy to strengthen its position in key global markets and enhance customer service.

Emile joins Newcells following a series of recent appointments to the US management and commercial teams, as part of the company’s strategy for continued expansion and technology innovation¹. In his new role, Emile will lead the international sales strategy, building on the team’s rapid growth and commercial success over the past year. His appointment will provide further support to Newcells’ global network, demonstrating a continued commitment to customer service and meeting the growing market demand for new approaches (NAM) in drug discovery.

Emile brings a wealth of commercial and technical experience spanning molecular biology and cutting-edge genomics technologies, with a proven track record of developing successful sales strategies and driving the implementation of innovative scientific solutions. Most recently, as UK Regional Business Manager for Bionano Genomics in California, he led the successful launch of the company’s novel optical genome mapping technology into the UK market, working closely to leverage the technology across industry, the NHS and academia.

During his five years at Horizon Discovery (now Revvity), Emile held various roles responsible for expanding and strengthening the customer network for the CRISPR/RNAi drug discovery and screening product portfolio in the UK, Europe and the US. He also gained experience in the Nordic market through his role at the epigenetics company Diagenode. Emile holds an MSc in Business Studies from Aston University and a BSc in Biomedical Sciences from Sheffield Hallam University.

Emile Shaffu, Sales Director at Newcells Biotech, said: ““I have focused on opportunities in high-innovation areas throughout my career. Newcells puts this at the forefront of its capabilities; combining unique expertise with cutting-edge technology to provide targeted solutions to researchers’ complex problems. I look forward to joining the company, working with the team, and leveraging my expertise to increase access to these industry-leading in vitro models – so we can take the guesswork out of drug development and accelerate clinical translation in more programs around the world.”

Dr. Mike Nicholds, CEO and co-founder of Newcells Biotech, commented: “Emile’s track record and proven leadership in the life sciences industry will play a key role as we expand our global footprint and advance our mission of improving the translation of preclinical research into first-in-human trials.” He added: “This announcement follows the recent appointment of Anthony Kayas and Catherine Ulich to our U.S. team and is an integral part of our growth strategy and commitment to serving our clients.”

Press release (June 11, 2024): Newcells Biotech strengthens US management team and team with key appointments